Introduction {#s1}
============

Fundamental knowledge in lipid science is well elucidated in terms of the fat molecule's contribution to total caloric needs, metabolic pathways of energy production, utilization, and storage in the human system. Further, the differentiation of fats based on chemical structure has led to an understanding on metabolic risks associated with atherogenecity in the non-critical status ([@B70]). On the other hand, benefits of lipid emulsions (LEs) in parenteral therapy has been evolving since the 1960s. I interestingly, although LEs are been administered intravenously in critical care and long-term nutrition support, there is little knowledge regarding the compositional nature and metabolic outcomes related to the nature of lipids in these formulations. Lipids were a late macronutrient addition to parenteral nutrition (PN) formulation in the 1960s, with experimentation leading to formulation of a broad range of intravenous LE products from variable fat sources ([@B141]).

The first commercially available LE in 1961 was based exclusively on soybean oil, contributing \~ 50% from *n*-6 linoleic acid (LA) in its total fatty acid (FA) profile. But side effects related to the high LA content added to a higher oxidative stress burden in critically ill patients ([@B15]) leading to a decision to reduce the LA content in LEs, and opening the way for alternative LEs in parenteral applications ([@B133]). This development offers new challenges evidenced from emerging clinical studies with aspects relating to inflammation ([@B17]; [@B90]), immunomodulation ([@B132]), and clinical outcomes ([@B18]) been reviewed in specific patient populations. However, a collective examination of the functionality of LEs relating to the structure and composition of lipids and their properties to metabolic outcomes has not been related to parenteral therapy in literature. In contrast, core knowledge on metabolic effects of stereospecific positioning of FAs in triglyceride molecules in native and structured fats has been reviewed in the context of atherogenic and metabolic risk ([@B69]) in healthy humans.

Therefore, this review highlights the composition of FAs in LEs, other components in LEs, biological function of FAs, the metabolic properties of FAs in different LEs, and clinical evidence associated with the use of these LEs in surgery, critically ill, and long-term PN patients.

Fatty Acids {#s1_1}
-----------

The functionality of the triacylglycerol (TAG) molecules is determined by the type of FA esterified to the glycerol backbone and the stereospecificity of the linkage ([@B69]). Although FAs share the common structural formula of CH3(CH2)~X~COOH, the chain length of carbon atoms linked to the methyl and carboxyl groups varies ([@B53]), with 4 carbon atoms or less termed as short-chain FAs, 6--14 carbon atoms as medium chain, and above 14 carbon atoms classified as long-chain FAs. Again FAs can be reclassified according to the presence or absence of saturation between carbon bonds. The saturated FAs (SFAs) belonging to medium-chain triglycerides (MCTs) feature in some LE formulations. Longer carbon chains with the 22-carbon docosahexaenoic acid (DHA) and the 20-carbon eicosapentaenoic acid (EPA) are also known in LE formulations. Saturation and unsaturation between carbon atoms will determine the functionality and usability of the FAs ([@B16]; [@B71]; [@B17]; [@B18]; [@B90]). Thus, in discussing FAs, their classification according to carbon chain length, degree of saturation or unsaturation, and the location of double bonds need to be appreciated in the context of LEs.

The melting point of saturated oils used in LEs increase with increasing FAs chain length ([@B53]). Physically MCTs are liquid at room temperature ([@B125]) and have a higher melting point compared to unsaturated FAs. For this reason MCTs are blended with other long-chain FAs such as oleic acid, LA, α-linolenic acid, DHA, and EPA to reduce the melting point to facilitate administration via the intravenous route ([**Table 1**](#T1){ref-type="table"}). Contrarily, the presence of double bonds in the carbon chain length lowers the melting point which increases the liquidity of lipid at room temperature ([@B53]) ([**Table 1**](#T1){ref-type="table"}). Therefore the unsaturated MUFAs and polyunsaturated fatty acids (PUFAs) benefit lower melting points enabling the liquid state of LEs at room temperature compared to the more saturated MCTs.

###### 

Melting point of commonly used fatty acids in lipid emulsions ([@B53]).

  Chain length   Fatty acids        Melting point
  -------------- ------------------ ---------------
  C12:0          Lauric acid        44.8°C
  C18:1          Oleic acid         13.4°C
  C18:2          Linoleic acid      −5.0°C
  C18:3          α-Linolenic acid   −11.0°C

Other Components in LEs {#s1_2}
-----------------------

Other microcomponents in LEs such as phytosterols, α-tocopherol, emulsifiers, and vitamin K further confer functional characteristics. In practice, Vanek *et al*. (2012) has noted information on these additives may not be declared on the LE product label depending on country availability and local regulation.

### Phytosterols {#s1_2_1}

Phytosterols are plant-based and include sitosterol, campesterol, and stigmasterol, sharing a similar structure with cholesterol. In normal metabolism, less than 5% of sterols are absorbed with the rest entering the colon ([@B79]). However in children receiving PN infusion, Clayton *et al*. (1993) reported occurrence of cholestatic liver disease, likely attributed to the 100% uptake of phytosterols into systemic circulation. In this situation, liver metabolism favors the conversion of sterols to bile salts, which been less soluble than cholesterol, is likely to be precipitated. The accumulation of sterol precipitates within liver cells is the hallmark of cholestasis ([@B25]). Sterol precipitation inhibits rate-limiting cholesterol 7α-hydroxylase in the liver affecting bile acid secretion ([@B10]). [@B101] reported that accumulation of phytosterols in newborns' plasma and red blood cell membrane may induce PN-related cholestasis.

Indeed intravenous infusion of phytosterols in animal models, indicate its accumulation in the blood, liver, and bile, causing cholestasis ([@B62]). Cholestasis emerged as an issue with long-term use of LEs when incorporating olive oil in infants ([@B114]) or soybean oil in children ([@B25]).

### α-Tocopherol {#s1_2_2}

The main form of vitamin E used in LEs is tocopherol occurring as α, β, γ-, or ơ-isoforms ([@B55]). Addition of α-tocopherol into LEs is to prevent peroxidation in susceptible PUFA-rich lipids ([@B9]) because of unsaturated double-bonds ([@B103]).

[@B137] evaluated tocopherol isoform applications, and concluded that long-chain triglycerides (LCTs) in LEs formulated from soybean and safflower oils are predominantly γ-tocopherol, which provide little protection against lipid peroxidation compared to fish oil LE (FOLE) with the highest concentration of α-tocopherol ([@B137]). Therefore it is reasonable to increase the α-tocopherol concentration to protect soybean oil LEs against lipid peroxidation. In order to maintain LE stability, addition of α-tocopherol requires a separate administration ([@B122]). Thus, the tocopherol content of LEs is a critical factor in patient administration.

In animal models, some vitamin E isoforms show benefit in prevention of hepatic injury. [@B96] reported the use of α-tocopherol in pre-term piglets causing reduction in serum markers of hepatic injury and cholestasis. However, [@B107] observed that tocopherol alone was not effective in treatment and prevention of intestinal failure associated liver disease in infants. [@B32] proposed several mechanisms for the reduction of intestinal failure-associated liver disease in children using fish oil-based LE, reduced phytosterol load, increased α-tocopherol and *n*-3 PUFAs (DHA and EPA) content.

### Emulsifiers {#s1_2_3}

LEs consist of two immiscible liquid phases, oil in water. Phospholipids play the role of emulsifying agent to allow the dispersion of fat droplets in the aqueous phase ([@B36]). Main sources of phospholipid are soybean oil and egg yolk. Lecithin from egg yolk has non-polar (lipophilic) and polar (hydrophilic) properties, which allow the dispersion of the fat droplets in aqueous phase of the emulsion ([@B39]; [@B36]). Fat droplets are prevented from coalescing by an electrostatic barrier generated by the anionic charge of phospholipid polar ends dissociating toward the aqueous phase, enabling stability of LEs ([@B36]).

With excess emulsifier, liposomes are generated in vesicular form termed as phospholipid-rich particles, forming a bilayer in the aqueous phase of LE. The liposome content is greater in LEs with a lower percentage of oil due to the higher phospholipid:oil ratio ([@B40]; [@B39]). The greater liposomes generation potentiates inhibition of lipolysis of artificial chylomicron, and also contributes to abnormal lipoproteins such as Lipoprotein-X. Lipoprotein-X causes hypercholesterolemia, cholesterol accumulation, and increase in free cholesterol:esterified cholesterol plasma ratio in human studies ([@B39]). Therefore the extent of liposome metabolism disturbance in plasma depends on the oil concentration in the LE, infusion rate, and duration of infusion ([@B60]; [@B36]). It is noted that liposomes with diameter of \<80 nm have no purpose as an energy source ([@B39]).

### Vitamin K {#s1_2_4}

Phylloquinone or vitamin K1 is important for normal blood clotting, and a deficiency would prolong the clotting time ([@B55]). The dietary recommendation for vitamin K is 1 μg/kg for adults ([@B120]) but for patients on anticoagulant therapy, the content of vitamin K1 in LEs should be considered when prescribing coumarin-based anticoagulants ([@B106]). The vitamin K content per 100 g of lipids used in LE formulation varies ([@B120]; [@B106]), as indicated for olive oil (1.1--5.5 μg), soybean oil (150--300 μg), and safflower oil (6--12 μg).

Biological Function of LEs {#s2}
==========================

Absorption and Transport of LEs {#s2_1}
-------------------------------

FAs introduced intravenously bypass the intestinal lumen and directly enter blood circulation. This means bypassing digestion by lipases, solubilization by bile, uptake into intestinal enterocytes, or packaging into chylomicrons compatible for circulatory transport to target organs. Lipids infused intravenously are already packaged into artificial chylomicrons ready for transport to target organs ([@B19]). LE chylomicrons mimic the structural similarity of natural chylomicrons produced by intestinal enterocytes ([@B19]) excepting the spherical size, as LE chylomicrons vary between 200 and 500 nm depending on the type of oil and its concentration in the LE ([@B82]; [@B39]). With LCTs mean particle diameter is larger than for MCTs, and droplets in 20% emulsions are larger than with 10% emulsions ([@B82]). Ease of passage of LE chylomicrons through the smallest of capillaries is essential to prevent vascular occlusion and is enabled with particle size within 200--500 nm ([@B34]).

LE chylomicrons are hydrolyzed to yield FAs by lipoprotein lipase, and then transported to the liver to provide energy substrate similar to the fate of natural chylomicrons ([@B19]). Differentially, LCTs are transported in blood as chylomicrons while MCTs from partial uptake become free FAs which bind to albumin. The composition of the LE particle will influence the rates of hydrolysis and uptake of FAs as determined by the FA carbon chain length and the relative position of the FA on the glycerol backbone ([@B69]). Therefore, the shorter carbon chain length of MCTs are hydrolyzed by lipases at a faster rate compared to LCTs ([@B29]).

Metabolism of FAs in LEs {#s2_2}
------------------------

Transported long-chain FAs are activated at the outer mitochondrial membrane by adenosine tri-phosphate to form acyl-adenylates before catalysis by acyl-CoA synthase. The sulfhydryl group of CoA reacts with the acyl-adenylate to form acyl-CoA. Aided by carnitine, the activated long-chain FAs then get transported into the mitochondrial matrix. The acyl carnitine formed from the reaction of acyl-CoA with the hydroxyl group of carnitine diffuses into the inner mitochondrial membrane. The acyl group of acyl-CoA reacts with the hydroxyl group of carnitine to form acyl-carnitine which enables diffusion into the inner mitochondrial membrane. Once inside the mitochondrial membrane, the acyl group will be transferred back to acyl-CoA and carnitine is released. These transacylation reactions are catalyzed by fatty acyl-CoA:carnitine FA transferase ([@B7]).

Medium-chain FAs been saturated and having shorter carbon chains generate energy faster, as the route of its fat oxidation differs from the longer FAs. These FAs promote passive movement across the mitochondrial double membrane, independent from carnitine allowing for direct oxidation ([@B125]; [@B53]). Metabolically, single-source MCT infusion gives rise to ketone bodies, predominantly β-hydroxybutyrates, as incomplete oxidation of medium-chain FAs in the mitochondria via β-oxidation converts intermediate metabolites of acetyl-CoA to ketones ([@B3]; [@B125]).

As regards structured triglycerides (STG), symmetrical TAGs formed by medium-chain FAs esterified at the *sn*-1 and *sn*-3 positions of the glycerol backbone would facilitate faster hydrolysis by lipoprotein lipase ([@B60]; [@B69]). This facilitates faster uptake of long-chain monoglycerides into the cell, and medium-chain FAs to be transported into mitochondria for oxidation ([@B60]).

The metabolic process of assimilating *n*-3 or *n*-6 PUFAs is competitive depending on their concentration and incorporating desaturation and chain elongation ([@B53]). The pathways of metabolism are shown in [**Figure 1**](#f1){ref-type="fig"}. The preferential order of FA affinity for enzyme competition is in the order of α-linolenic \> linoleic \> oleic acid ([@B55]). With essential FA deficiency, a third FA route utilizing oleic acid, becomes an option in the biological system ([@B128]).

![Metabolic pathway of *n*-3 and *n*-6 PUFAs with desaturase and elongase enzymes. The affinity for *n*-6 PUFAs by these enzymes are higher compared to *n*-9; A, acid; C, carbon; PUFA, polyunsaturated fatty acid. References ([@B55]; [@B128]).](fphar-11-00506-g001){#f1}

Functionality of LEs {#s3}
====================

Unlike SFAs and MUFAs, humans are unable to synthesize PUFAs endogenously, particularly α-linolenic acid and LA, due to the lack of Δ-12 and Δ-15 desaturases which enable chain elongation ([@B53]; [@B136]). Therefore supplementation of these FAs is vital in LEs. When α-linolenic acid and LA are supplemented, they undergo systemic chain elongation and desaturation driven by liver enzymes to produce a series of longer chain FAs which acquire additional double bonds ([@B136]). Both these PUFAs maintain membrane structure and fluidity, tissue permeability and cell signaling, and are precursors of important lipid mediators ([@B14]; [@B136]). EPA and DHA generated from the chain elongation of α-linolenic acid biologically become structural components of cell membranes, especially in the brain and the retina.

Oleic acid originating from olive oil is the major form of MUFA in LEs and even available as free FAs. When LA is scarce and oleic acid is available in excess, oleic acid will competitively inhibit enzymes involved in arachidonic acid formation ([@B30]). Evidence from animal and human studies suggest that PUFA and MUFA increase the activity of lipoprotein lipase which enhances TAG clearance during postprandial lipemia ([@B140]). In contrast, MCTs in LEs sourced from coconut oil carry shorter carbon chain FAs that are saturated, allowing ready oxidization in mitochondria and utilization as fuel for energy ([@B125]; [@B53]).

With fish oil supplementation, the *n*-3-PUFAs outstrip the arachidonic acids competitively in the enzyme-catalyzed eicosanoid synthesis pathway to generate eicosanoids of three-series prostaglandins, thromboxanes, and five-series leukotrienes, which are less proinflammatory ([@B130]; [@B14]; [@B51]). Therefore, reduced *n*-6:*n*-3 PUFA ratio of FOLE results in less-proinflammatory eicosanoid derivatives. Changes in the ratio of leukotrienes C~5~ to C~4~ production by peripheral blood mononuclear cells was highest when a mixture of 2:1 of the two FAs were used, and this ratio exerts the most favorable modulation of lipid mediator synthesis ([@B92]).

LEs in Formulation {#s4}
==================

The nature of oil used in LE formulations, depending on source and percentage contribution to the energy matrix, will determine the key functionalities between LEs. These differences account for their additional benefits or detrimental effects depending on prolonged use for critically ill or home PN patients. [**Table 2**](#T2){ref-type="table"} describes commercially available LEs and other components in PN for intravenous application. Soybean oil, predominantly *n*-6 PUFAs rich was combined with saturated MCTs identified as second generation LE. The third generation of LE primarily decreased the load of *n*-6 PUFAs by 75% with olive oil. By the year 2000, fish oil either alone or in combination with one or more of the based vegetable oils yielded the fourth generation LEs. Details of each LE will be discussed in the following sections. [**Table 3**](#T3){ref-type="table"} compares the concentrations of FAs from vegetable and fish oil sources. Their profile therefore varies in terms of therapeutic benefits and subsequent discussions reflect these aspects.

###### 

Commercially available lipid emulsions in parenteral nutrition.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Type of LE                       1st Generation (1960s to 1970s)\   2nd Generation (since 1985)   3rd Generation (since 1990s) Olive Oil LE   4th Generation (since 2000)                                            
                                   Soybean Oil LE                                                                                                                                                                      
  -------------------------------- ---------------------------------- ----------------------------- ------------------------------------------- ----------------------------- --------------- ------------------------ --------------------------------
  Oil source (% by wt)             100% SO                            50% SO, 50% CO                64% SO, 36% CO                              20% SO, 80% OO                100% FO         50% CO, 40% SO, 10% FO   30% SO, 30% CO, 25% OO, 15% FO

  Commercial name                  Intralipid® 20%                    Lipofundin MCT/LCT® 20%       Structolipid® 20%                           ClinOleic® 20%                Omegaven® 10%   Lipiderm/Lipoplus® 20%   SMOFLipid® 20%

  Ratio of *n*-6:*n*-3 PUFAs       7:1                                7:1                           7:1                                         9:1                           1:8             2.7:1                    2.5:1

  Fat content (g/L)                200                                200                           200                                         200                           100             200                      200

  Molecular weight                 865                                634                           683                                         873                           882             NA                       732

  PH                               8.0                                6.5--8.5                      8.0                                         7.0--8.0                      7.5--8.7        6.5--8.5                 8.0

  Osmolality (mOsmol/L)            350                                380                           350                                         270                           273             410                      380

  α-Tocopherol (mg/L)              38                                 85 ± 20                       6.9                                         32                            150--296        190 ± 30                 200

  Phytosterols (μg/ml)             342.89 ± 5.87                      278.14 ± 5.09                 345.85 ± 1.64                               274.38 ± 2.6                  3.66 ± 0.59     NA                       207

  FAC (% by weight of total FAs)                                                                                                                                                                                       

   SFA                             15                                 59.4                          46.3                                        14.5                          21.2            58.3                     81.1

   MUFA                                                                                                                                                                                                                

    OA                             24                                 11                            14                                          62.3                          15.1            7.9                      55.3

   PUFA                                                                                                                                                                                                                

    LA                             53                                 29.1                          35                                          18.7                          4.4             24.4                     37.2

    α-LA                           8                                  4.5                           5                                           2.3                           1.8             3.3                      4.7

    AA                             0.1                                0.2                           NA                                          0.5                           2.1             NR                       1.0

    EPA                            NA                                 NA                            NA                                          NA                            19.2            3.1                      4.7

    DHA                            NA                                 NA                            NA                                          0.5                           12.1            2.3                      4.4
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AA, arachidonic Acid, CO, coconut oil; DHA, docosahexanoic acid; EPA, eicosapentaenoic acid, FAC, fatty acids concentration; FO, fish oil; LCT, long-chain triglycerides; LE, lipid emulsion; MCT, medium-chain triglycerides; MUFA, monounsaturated fatty acids; NA, not available; NR, not reported; OO, olive oil; PUFA, poly unsaturated fatty acids; SMOF, soybean oil, coconut oil, olive oil and fish oil; SFA, saturated fatty acids; SO, soybean oil. Fatty Acids Concentration based on percentage by weight, percentages do not add up to 100% because not all FAs are listed. **References:** [@B133]; [@B136]; [@B128]; [@B144].

###### 

Fatty acid composition in selected plant and fish sources used in intravenous lipid emulsions.

  FAC (% by weight)      Plant sources^\*^   Fish species^\#^                                                   
  ---------------------- ------------------- ------------------ ------- ------- ------- ------- ------- ------- -------
  Caprylic acid (8:0)    NR/ND               NR/ND              8       NR/ND   NR/ND   NR/ND   NR/ND   NR/ND   NR/ND
  Capric acid (10:0)     NR/ND               NR/ND              7       NR/ND   NR/ND   NR/ND   NR/ND   NR/ND   NR/ND
  Lauric acid (12:0)     NR/ND               NR/ND              48      NR/ND   NR/ND   NR/ND   NR/ND   NR/ND   NR/ND
  Myristic acid (14:0)   NR/ND               NR/ND              16      5.6     7.0     7.4     3.9     2.4     1.6
  Palmitic acid (16:0)   11                  10                 9       17.6    17.1    17.4    16.6    11.2    23.2
  Stearic acid (18:0)    4                   2                  2       NA      NA      NA      NA      NA      NA
  Oleic acid (18:1)      23                  78                 7       18.9    19.2    15.2    20.6    24.0    16.1
  Linoleic acid (18:2)   53                  7                  2       1.8     1.6     2.4     2.3     3.1     1.2
  α-LA (18:3)            8                   1                  NR/ND   1.3     1.3     0       2.5     5.2     1.8
  EPA (20:5)             NR/ND               NR/ND              NR/ND   7.4     8.9     13.1    13.9    5.7     5.4
  DPA (22:5)             NR/ND               NR/ND              NR/ND   1.7     0.6     0.7     0.9     5.1     1.9
  DHA (22:6)             NR/ND               NR/ND              NR/ND   11.6    10.8    22.2    21.1    19.8    26.8

α-LA, alpha-linolenic acid; DHA, docosahexanoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; FAC, fatty acid concentration; NA; not available; ND; not detected; NR, not reported. FAC, fatty acids concentration based on percentage by weight, percentages do not add up to 100% because not all FAs are listed. Fish species from marine families of Carangidao, Clupeidae, Engraulidae, Osmeridae, Salmonidae, Scombridge (a--f).\*Reference for plant sources: [@B62]; [@B44]; [@B83].^\#^Reference for fish species: [@B35].

Jadad scoring ([@B63]) was applied to rate quality of cited randomized controlled trials evaluating various LEs formulations, and detailed in [**Supplementary File**](#SM1){ref-type="supplementary-material"} ([**Table 1**](#T1){ref-type="table"}). Overall, 8 studies ([@B45]; [@B117]; [@B3]; [@B65]; [@B121]; [@B86]; [@B123]; [@B31]) were rated with a Jadad score of 1, 19 studies ([@B33]; [@B91]; [@B92]; [@B5]; [@B109]; [@B131]; [@B42]; [@B115]; [@B138]; [@B49]; [@B67]; [@B87]; [@B23]; [@B51]; [@B61]; [@B110]; [@B83]; [@B145]; [@B142]) scored 2, 11 studies ([@B130]; [@B20]; [@B80]; [@B44]; [@B139]; [@B8]; [@B4]; [@B99]; [@B135]; [@B52]; [@B24]) scored 3, 6 studies ([@B112]; [@B73]; [@B78]; [@B127]; [@B134]; [@B102]) scored 4, and 11 studies ([@B11]; [@B72]; [@B119]; [@B77]; [@B1]; [@B66]; [@B57]; [@B28]; [@B89]; [@B50]; [@B84]) scored 5.

Soybean Oil-Based LEs {#s4_1}
---------------------

Soybean oil-based LEs (SOLEs) were the primary LEs in PN therapy, formulated with the objective of preventing the development of essential FA deficiency ([@B48]), as well as to offset the glucose load to prevent hyperglycemia ([@B116]). The total FA composition profile of soybean oil includes \~53% LA (18:2*n*-6), \~23% oleic acid, and \~8% α-linolenic acid ([@B53]). About 84% of soybean oil carries three 18-carbon, long-chain unsaturated FAs with the remaining \~15% from SFAs such as stearic acid \~4% and palmitic acid \~11% ([@B128]; [@B68]). SOLEs have high *n*-6 PUFA compared to *n*-3 PUFA with ratio of 7:1 ([@B133]). Commercially available LEs with 100% soybean oil is listed in [**Table 2**](#T2){ref-type="table"}.

Soybean oil is naturally rich in phytosterols, mainly \~60% β-sitosterol followed by \~20% each of campesterol and stigmasterol ([@B53]). Phytosterol concentration in soybean oil is \~320 mg/100 g oil ([@B129]). The abundance of phytosterols in SOLE is associated with the severity of *intestinal failure associated liver disease* in home PN patients ([@B38]; [@B81]). The concentration of α-tocopherol in soybean oil is \~7.5 mg/100 g oil but γ-tocopherol content \~80 mg/100 g oil ([@B53]) been greater, contributes to 10% of vitamin E's biological activity ([@B9]).

### Comparative Studies of SOLEs *vs* Lipid Free Glucose Infusions {#s4_1_1}

[**Table 4**](#T4){ref-type="table"} reports on immuno-inflammatory and clinical outcomes of trials comparing the use of SOLE in PN with lipid free PN admixtures. Some studies reported either no change or immunostimulatory effects when SOLE was used compared to lipid-free PN admixtures in surgical patients ([@B33]; [@B91]; [@B76]; [@B68]). Li *et al*. (2007) and Kagawa *et al*. (2012) suggested LE infusion is dose-dependent and the infusion rate at 0.09--0.12 g/kg/h does not alter human immune function ([@B76]; [@B68]).

###### 

Clinical outcomes of randomized controlled trials categorized as per lipid emulsion formulation type.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.   Type of LE   Patient subgroups   Significant outcomes                                                                                                      References
  ----- ------------ ------------------- ------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------
  1\.   SOLE         Surgery             Nutrition                                                                                                                 

                                          ↑ glucagon, cumulative NB negative                                                                                       ([@B42])

                                         Immune and inflammatory                                                                                                   

                                          ↑ PMN cells                                                                                                              ([@B33])

                                          ↑ IL-2                                                                                                                   ([@B91]; [@B117])

                                          ↓ LAK cell activity                                                                                                      ([@B117])

                                          ↑ IL-6, ↑ CRP, ↓ lymphocyte proliferation                                                                                ([@B42])

                                          ↑ T cells and helper T cells, ↑ ADCC function                                                                            ([@B91])

                                          ↓ Bacteria killing mediated by neutrophils                                                                               ([@B131])

                                         Clinical                                                                                                                  

                                          ↓ Sepsis score                                                                                                           ([@B33])

                     ICU                 Immune and inflammatory                                                                                                   

                                          ↓ Helper/suppressor T cells ratio\                                                                                       ([@B45])
                                         Clinical                                                                                                                  

                                          ↑ Infection, ↑ ICU stay, ↑ hospital stay, ↑ duration MV                                                                  ([@B5])

  2\.   Physical     Surgery             Nutrition                                                                                                                 

        MCT/LCT                           ↓ Body weight, ↓ TG, ↑ β hydroxybutyrate                                                                                 ([@B65])

                                          ↑ Pre-albumin                                                                                                            ([@B23])

                                          ↑ Insulin                                                                                                                ([@B65]; [@B23])

                                         Immune and inflammatory                                                                                                   

                                          ↑ NK and ↑ LAK cell activity Clinical                                                                                    ([@B117])

                                          ↓ Intra-abdominal infection                                                                                              ([@B49])

                                          ↓ Mortality                                                                                                              ([@B49])

                     ICU                 Nutrition                                                                                                                 

                                          ↓ Negative NB                                                                                                            ([@B3]; [@B44])

                                          ↑ Retinol binding protein, ↑ insulin                                                                                     ([@B44])

                                         Immune and inflammatory                                                                                                   

                                          No change in immune markers                                                                                              ([@B61])

                                         Clinical                                                                                                                  

                                          ↑ Oxygen consumption, VO~2~                                                                                              ([@B121])

                                          ↓ Duration of MV                                                                                                         ([@B61])

  3\.   STG-LE       Surgery             Nutrition                                                                                                                 

                                          No ↑ TG, No ↑ ASAT, No ↑ ALAT, NB positive                                                                               ([@B20])

                                          Improved cumulative NB                                                                                                   ([@B20]; [@B73])

                                          Less ↑ TG                                                                                                                ([@B73])

                                          ↑ Carbon dioxide production, ↑ whole-body fat oxidation, ↑ free fatty acid, ↑ plasma glycerol, ↑ 3-hydroxybutyric acid   ([@B112])

                     ICU                 Nutrition                                                                                                                 

                                          Improved cumulative NB                                                                                                   ([@B78])

  4\.   OOLE         HPN                 Cellular fatty acid changes                                                                                               

                                          ↑ γ-LA, ↑ oleic acid, ↑ mead acid                                                                                        ([@B127])

                     Surgery             Nutrition                                                                                                                 

                                          ↑ Body weight                                                                                                            ([@B31])

                                          ↓ TBARS                                                                                                                  ([@B31])

                                          ↑ ALP, ↑ GGT, ↑ total protein, ↑ albumin, ↓ total bilirubin                                                              ([@B99])

                                         Clinical                                                                                                                  

                                          No changes on catheter infections                                                                                        ([@B99])

  5\.   FOLE         Surgery             Nutrition                                                                                                                 

                                          ↑ α-Tocopherol                                                                                                           ([@B80]; [@B72]; [@B51]; [@B139])

                                          ↓ AST, ↓ ALT                                                                                                             ([@B72]; [@B102])

                                          ↓ α-GST, ↓TG                                                                                                             ([@B102])

                                          ↓ LDL                                                                                                                    ([@B83])

                                          ↑ APTT,                                                                                                                  ([@B135])

                                          ↓ Total bilirubin,                                                                                                       ([@B72]; [@B135])

                                          ↓ Glucose                                                                                                                ([@B142])

                                          Less ↓ HDL, less ↓ free fatty acid                                                                                       ([@B84])

                                          ↑ Body weight, ↓ TBARS                                                                                                   ([@B31])

                                         Cellular fatty acid changes                                                                                               

                                          ↑ EPA or DHA                                                                                                             ([@B92]; [@B109]; [@B80]; [@B87]; [@B72]; [@B51]; [@B119]; [@B8])

                                          ↑ ALA                                                                                                                    ([@B92])

                                          ↑ EPA/AA ratio                                                                                                           ([@B109]; [@B51]; [@B119])

                                          ↓ LA                                                                                                                     ([@B80])

                                          ↑ Total *n*-3 PUFA, ↑ *n*-3:*n*-6 PUFA ratio                                                                             ([@B72]; [@B51]; [@B119])

                                         Immune and inflammatory                                                                                                   

                                          ↓ IL-6                                                                                                                   ([@B25]; [@B87]; [@B77]; [@B145]; [@B28])

                                          ↓ LTB~4~                                                                                                                 ([@B130])

                                          ↓ TNF-α                                                                                                                  ([@B130]; [@B87]; [@B145])

                                          ↑ TNF-α                                                                                                                  ([@B115]; [@B135])

                                          ↑ HLA-DR                                                                                                                 ([@B25])

                                          ↑ IL-2                                                                                                                   ([@B115])

                                          ↑ LTB~5~, ↑ LTB~5~/LTB~4~ ratio                                                                                          ([@B130]; [@B67]; [@B51]; [@B139]; [@B135])

                                          ↓ IL-1β, and ↓ IL-8                                                                                                      ([@B87])

                                          ↑ CD4+/CD8+                                                                                                              ([@B115]; [@B77])

                                          ↓ CD4+/CD8+                                                                                                              ([@B145])

                                          ↑ NF-Kβ                                                                                                                  ([@B135])

                                          ↓ IL-10                                                                                                                  ([@B28])

                                         Clinical                                                                                                                  

                                          ↓ Post-operative stay on medical ward                                                                                    ([@B25])

                                          ↓ Length of hospital stay                                                                                                ([@B51]; [@B66]; [@B145])

                                          ↓ Infection rates                                                                                                        ([@B1])

                                          ↓ Duration of SIRS                                                                                                       ([@B66]; [@B145])

                     ICU                 Nutrition                                                                                                                 

                                          ↑ Albumin                                                                                                                ([@B52])

                                         Cellular fatty acid changes                                                                                               

                                          ↑ EPA and DHA                                                                                                            ([@B86]; [@B87]; [@B134]; [@B4])

                                         Immune and inflammatory                                                                                                   

                                          ↓ IL-6                                                                                                                   ([@B87]; [@B4]; [@B123]; [@B57]; [@B89])

                                          ↓ TNF-α                                                                                                                  ([@B87]; [@B4]; [@B123]; [@B57])

                                          ↓ IL-10                                                                                                                  ([@B4]; [@B123])

                                          ↑ Neutrophil inositol phosphate, ↑ PAF, ↑LTB~5~                                                                          ([@B86])

                                          ↑ Respiratory burst                                                                                                      ([@B86])

                                          ↓ IL-8                                                                                                                   ([@B87]; [@B57])

                                          ↓ CRP                                                                                                                    ([@B134]; [@B52])

                                          ↓ IL-1β                                                                                                                  ([@B87]; [@B4])

                                          ↓ IL-1                                                                                                                   ([@B123]; [@B57])

                                          ↓ LTB4                                                                                                                   ([@B110]; [@B52])

                                          ↓ IFN-γ                                                                                                                  ([@B57])

                                         Clinical                                                                                                                  

                                          Improvement in oxygenation index                                                                                         ([@B134]; [@B4])

                                          ↓ CRRT days                                                                                                              ([@B134])

                                          ↓ Hospital stay                                                                                                          ([@B4])

                                          ↓ Nosocomial infections, ↑ predicted time free of infection                                                              ([@B50])

                                          ↓ 60-day mortality                                                                                                       ([@B24])

                     HPN                 Cellular fatty acid changes                                                                                               

                                          ↑EPA,↑ DHA, ↑DPA in erythrocytes,platelets, serum phospholipids                                                          ([@B11])
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AA, arachidonic acid; ADCC, antibody-dependent cellular cytotoxicity; ALA, α-linolenic acid; ALAT, alanine aminotransferase; ALP, alkaline phosphatase; ALT, alanine transaminase; APTT, activated partial thromboplastin time; ASAT/AST, aspartate aminotransferase; CD4/CD8+, T4 helper cells/T8 suppressor cells; CRP, C-reactive protein; CRRT, continuous renal replacement therapy; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; FOLE, fish oil lipid emulsion; GGT, gamma-glutamyl transferase; GST, glutathione S-transferase; HDL, high-density lipoprotein; HLA-DR, human leukocyte antigen-antigen D related; HPN, home parenteral nutrition; ICU, intensive care unit; IFN, interferon; Ig, immunoglobulin; IL, interleukin; LA, linoleic acid; LAK, lymphokine activated killer; LDL, low-density lipoprotein; LTB~4~, leukotriene B~4~; LTB~5~, leukotriene B~5~; MV, mechanical ventilation; NB, nitrogen balance; NK, natural killer; NF-Kβ, nuclear factor kappa β; OOLE, olive oil lipid emulsion, PAF, platelet activating factor; PMN, polymorphonuclear; PN, parenteral nutrition; PO~2~/FiO~2~, partial pressure of oxygen/fraction of inspired oxygen; PUFA, polyunsaturated fatty acid; SIRS, systemic inflammatory response syndrome; SOLE, soybean oil-based lipid emulsion; STG-LE, structured triglyceride lipid emulsion; TBARS, thiobarbituric acid-reactive substances; TG, triglyceride; TNF, tumor necrosis factor; VO~2~, oxygen consumption. For more details, please refer to [**Supplementary File**](#SM1){ref-type="supplementary-material"} ([**Table 1**](#T1){ref-type="table"}).

Evidence is conflicting associating SOLE use with clinical risk ([**Table 4**](#T4){ref-type="table"}) ([@B45]; [@B117]; [@B5]; [@B131]; [@B42]). Reductions in the ratio of helper to suppressor T-cells ([@B45]), lymphokine-activated killer cell activity ([@B117]), lymphocyte function ([@B5]), lymphocyte proliferation ([@B42]), and bacteria killing by neutrophils ([@B131]) have been reported. Post-surgical patients with severe stress, experienced increased interleukin-6 (IL-6) and C-reactive protein (CRP) levels after receiving SOLE compared to lipid-free PN. The high ratio of *n*--6:*n*--3 PUFAs in SOLE poses greater risk toward inflammatory response ([@B42]). LA metabolism promotes eicosanoid formation via enzymatic chain elongation, known to be proinflammatory mediators affecting macrophage, neutrophil and lymphocyte function ([@B136]).

SOLE use is also associated with risk of adverse clinical outcomes. A meta-analysis reported higher infectious complication rates in surgical and intensive care patients on SOLE compared to lipid-free PN ([@B59]). Polytrauma patients on SOLE for 10 days had increased number of days on mechanical ventilation, and longer stay in intensive care and hospital stay ([@B5]). However one study reported reduced severity of infections in gastrointestinal surgery patients on SOLE compared to lipid-free PN ([@B33]). In contrast, patients undergoing bone marrow transplantation did not experience increased incidence of bacterial or fungal infections when infused with SOLE providing less than 30% energy/day ([@B75]).

#### Issues Associated With Use of SOLEs {#s4_1_1_1}

The reticuloendothelial system participates in clearance of lipid particles associated with infusion of LEs. However, long-term administration of SOLE may deleteriously affect the reticuloendothelial system function ([@B118]). Another risk of long-term use of SOLE is hepatotoxicity attributed to phytosterol content ([@B113]; [@B81]).

Physical Mixture MCT/LCT LEs {#s4_2}
----------------------------

Concern about adverse effects from SOLE related to immuno-inflammatory and clinical risks led to the development of the physical mixture MCT/LCT. Physical mixtures combining MCT with LCT were initially formulated with coconut oil providing 50% of the MCT substrate with the remaining 50% from soybean oil. The MCT/LCT physical mixture formulation with effective manipulation of the percentage proportion of long-chain soybean oil with a shorter-chain FA, enabled the required reduction in the *n*-6 PUFA content in SOLEs. Coconut oil is the principal source of medium-chain FAs with lauric acid contributing 48% FA concentration, 8% caprylic acid, and 7% capric acid. Other fractions of FAs in coconut oil include 16% myristic acid, 9% palmitic acid, 2% stearic acid, 7% oleic acid and 2% LA ([@B53]). Typical commercial MCT/LCT LE formulations in use are detailed in [**Table 2**](#T2){ref-type="table"}.

Total phytosterol concentration in coconut oil (67.8 mg/100 g) is lower compared to soybean oil (\~320 mg/100 g) with β-sitosterol contributing \~70%, followed by stigmasterol \~18% and campesterol \~11% ([@B129]). The α-tocopherol concentration of coconut oil is very low at 0.5 mg/100 g oil compared to soybean oil \~7.5 mg/100 g oil ([@B53]) which implies a lower phytosterol and α-tocopherol content in the physical mixture of MCT/LCT LEs, compared to SOLE.

### Comparative Studies of MCT/LCT LEs With SOLEs {#s4_2_1}

[**Table 4**](#T4){ref-type="table"} summarizes randomized controlled trials and crossover studies that have compared the effects of MCT/LCT LE and SOLE in abdominal surgery, critically ill, and long-term PN patients. Most of these studies concentrated on metabolic outcomes followed by clinical benefits. Two studies showed no influence of MCT/LCT LE on immune function in surgery and critically ill patients ([@B45]; [@B117]). In terms of immunomodulation there was no change in the ratio of helper to suppressor T-cells after MCT/LCT infusion, in contrast to a significant decrease in the ratio observed with SOLE ([@B45]). In patients after gastrointestinal cancer surgery, MCT/LCT infusion increased natural killer cell activity and lymphokine activated killer activity compared to SOLE ([@B117]). These findings are suggestive of improved immune function in the patient group receiving MCT/LCT LE. Indeed, MCTs do not depress the reticuloendothelial system function as evidenced from animal and human studies ([@B56]; [@B64]). MCTs, being saturated cannot participate in eicosanoid synthesis and are not precursors for prostaglandins. Therefore they do not affect the production of inflammatory mediators during stress and illness in relation to *n*-6 PUFA ([@B105]).

Significant metabolic outcomes observed in intensive care and abdominal surgery patients administered with MCT/LCT LE infusion compared to SOLE are related to increase in plasma ketones ([@B2]; [@B65]), non-esterified FAs ([@B2]), insulin ([@B65]; [@B44]; [@B23]), prealbumin ([@B23]), retinol binding protein ([@B44]), and improved nitrogen balance ([@B3]; [@B44]). Contrarily one study did not observe any of these effects ([@B97]).

Increased oxygen consumption in acute respiratory distress syndrome patients ([@B121]), shorter weaning time from ventilator in chronic obstructive pulmonary disease patients ([@B61]), and significant reduction in postoperative complications and mortality in preoperative surgery patients ([@B49]) are some clinical benefits attributed to MCT/LCT LE administration compared to SOLE.

#### Issues Associated With Use of MCT/LCT LEs {#s4_2_1_1}

Since MCT oils are significantly low in essential FAs, dependency as a sole substrate of fat would be an issue in clinical applications unless combined with an *n*-6 PUFA-rich fat substrate to make up this deficit ([@B95]). A combination ratio of 1:1 for MCT and LCT is sufficient to prevent essential FA deficiency in long-term PN administration with an optimal dose of 0.41 ± 0.22 g/kg/day ([@B21]). Hypertriglyceridemia with initial infusion of MCTs is noted with MCT/LCT LE administration ([@B2]) and this is attributed to faster hydrolysis of MCTs. Additionally, generation of ketone metabolites, predominantly β-hydroxybutyrates ([@B3]) are associated with MCT/LCT LE and may induce increased insulin production ([@B95]).

Structured Triglyceride LEs {#s4_3}
---------------------------

The physical mixture of MCT/LCT LEs evolved further with the introduction of STGs as a new substrate option ([@B22]). The predominant commercial LE is a structured mix of 64% LCT from soybean oil and 36% of MCT from coconut oil ([**Table 2**](#T2){ref-type="table"}). STGs are used as a lipid source in 3-in-1 commercial PN Bag.

Unlike physical mixtures, an STG-LE is formulated by first hydrolyzing soybean and coconut oils to free FAs, before interesterification in the presence of chemical or enzyme catalysts. Essentially medium-chain FAs (from coconut oil) and long-chain FAs (from soybean oil) are randomly reassigned on the glycerol backbone, generating new TAG molecular species ([@B69]). In STG-LEs, medium-chain FAs are preferentially positioned at the *sn*-1 and *sn*-3 positions of the TAG molecule with a long-chain FA occupying the *sn*-2 position ([@B22]). The choice of preferential placement of medium-chain FAs at the *sn-1* or *sn-3* position enables faster oxidation of energy substrates. An immunomodulating effect may be associated with STG if arachidonic acid, EPA, or DHA is incorporated at the *sn*-2 position ([@B22]). Additionally, favorable stereospecific positioning of medium-chain FAs in the molecular structure of STG facilitate faster triglyceride clearance and utilization as noted by [@B69]. MCT/LCT LE carries more MCT compared to STG-LE (50% *vs* 36%) which fulfills the desired functionality of rapid hydrolysis compared to LCTs ([@B2]).

### Comparative Studies of STG-LEs With SOLEs and Physical Mixture MCT/LCT LEs {#s4_3_1}

[**Table 4**](#T4){ref-type="table"} reports on metabolic outcomes associated with STG-LE use compared to SOLE and MCT/LCT LE in surgery and critically ill patients. There is improved nitrogen retention in post-surgical patients receiving STG-LE compared to SOLEs and MCT/LCT LEs ([@B73]; [@B78]). Fat oxidation rate and 3-hydroxybutyric acid concentrations were found to be higher in the post-surgical STG-LE group, who received STG-LE for one day and SOLE the next day or *vice versa* for 6 days with lipid dose-dependence while maintaining amino acids and dextrose concentrations ([@B112]). Conflicting findings related to differences in lipid infusion rates, switching of LE regimens daily, and different glucose:lipid ratios prescribed across study groups have been reported ([@B112]; [@B6]; [@B20]).

The reduced risk of hypertriglyceridemia was noted in patients administered with STG-LE in post-surgical patients for 5 days ([@B20]; [@B73]) compared to MCT/LCT LEs. This effect could be attributed to favorable stereospecific positioning of FAs in the molecular structure of STG enabling faster triglyceride clearance and utilization ([@B69]).

Meta-analysis of 21 clinical trials with critically ill patients (n = 4) and surgical patients (n = 17) concluded short-term administration of STG-LE (5 to 7 days) was significantly associated with improved nitrogen balance, increased plasma proteins, reduced plasma triglycerides, improved liver function parameters, and reduced adverse events and length of hospital stay compared to physical mixture MCT/LCT LEs ([@B143]).

STG-LEs do not show any influence on the reticuloendothelial system, unlike the inhibition of reticuloendothelial system function shown by LCT ([@B22]).

#### Issues Associated With Use of STG-LEs {#s4_3_1_1}

A lower α-tocopherol (6.9 mg/L) content adds to greater lipid peroxidation risk and higher phytosterols (\~350 μg/ml) compared to MCT/LCT LE (\~280 μg/ml), therefore adding to liver toxicity risk ([@B128]; [@B144]). Naber and Krumel, (2002) observed STG-LE administration generated greater production of the ketone metabolite, β-hydroxybutyrate indicating a faster oxidation rate compared to physical mixture MCT/LCT ([@B95]). The impact of this metabolite on insulin and glycemic status of patients in therapy remains unreported.

Olive Oil LEs {#s4_4}
-------------

Another option to reduce *n*-6 PUFAs is with olive oil as a principal component by 80% replacement of soybean oil. The FA composition of olive oil reflects \~80% of the nonessential *n*--9 oleic acid with lesser proportions of the essential *n*--6 LA \~7% and the saturated palmitic acid \~10% ([@B53]). The *n*-3 PUFA in olive oil is negligible ([**Table 2**](#T2){ref-type="table"}). The small content of LA in olive oil explains the need to include an *n*-6 PUFA-rich source such as soybean oil to prevent essential FA deficiency. A formulation of olive oil LE (OOLE) blending \~20% soybean oil with \~80% olive oil in volume is commercially available ([**Table 2**](#T2){ref-type="table"}). Olthof *et al*. (2015) who studied 30 home PN patients receiving a combination of olive oil (80%) and soybean oil (20%) for 3 months at five times a week, reported their patients did not develop essential FA deficiency ([@B98]).

Phytosterol concentration in olive oil is \~190 mg/100 g oil with 70% in the form of β-sitosterol ([@B129]). Olive oil also contains significant amounts of α-tocopherol ([@B111]) at \~12 mg/100 g oil ([@B53]), and thus provides sufficient protection against lipid peroxidation ([@B111]; [@B13]).

### Comparative Studies of OOLEs With SOLEs and Physical Mixture MCT/LCT LEs {#s4_4_1}

[**Table 4**](#T4){ref-type="table"} summarizes trials on OOLE compared to SOLE and physical mixture MCT/LCT LE in abdominal surgery, critically ill, and long-term PN patients. In terms of immuno-inflammatory outcomes, there was no difference in inflammatory, immune function markers, and pro-inflammatory cytokines (TNF-α and IL-6) in both critically ill ([@B126]) and abdominal surgery ([@B31]) patients randomized to receive either SOLE or MCT/LCT physical mixture *vs* OOLE. Similarly, inflammatory markers in home-PN patients on OOLE for 3 months were not different from baseline status ([@B108]). Oleic acid predominant in olive oil, is hypothesized to offset immune system impairment when in combination with *n*-6 PUFA ([@B94]; [@B26]). Metabolically, oleic acid does not influence the arachidonic eicosanoid pathway and is not a precursor for eicosanoids ([@B13]). Therefore a lesser proinflammatory response compared to soybean oil is likely.

Benefits on metabolic outcomes were reported by [@B99]. Significant increases in total protein and albumin followed by reduction in total bilirubin levels were reported in abdominal cancer surgery patients infused with OOLE for 7 days compared to SOLE. Weight gain has also been observed in patients receiving OOLE ([@B31]). Home-PN patients with OOLE infusion over 2 months ([@B100]), or 3 months ([@B108]; [@B104]), post-abdominal surgery ([@B104]; [@B99]), and severely ill burns patients ([@B43]) infused with OOLE did not have abnormal liver function tests. However evidence on clinical benefit of OOLE compared to MCT/LCT LE and STG-LE is still scarce.

The single unsaturated double-bond of oleic acid which characterizes OOLE likely mediates less lipid peroxidation and oxidative stress compared to LEs with *n*-6 and *n*-3 PUFAs ([@B111]). Animal studies ([@B37]) and human studies with children ([@B47]) and adults ([@B31]) have reported reduction in thiobarbituric acid--reactive substances implying lowest risk of oxidative stress when given OOLE.

#### Issues Associated With Use of OOLEs {#s4_4_1_1}

The impact of optimizing *n*-9 MUFA from OOLE is unknown in terms of whether there is competitive inhibition on the endogenous synthesis of *n*-3 PUFAs. This is because generation of gondoic acid and nervonic acid from oleic acid elongation have been reported to add on cardiovascular mortality risk ([@B30]).

Fish Oil LEs {#s4_5}
------------

Another option to reduce *n*-6 PUFA was to increase *n*-3 PUFAs with FOLE. Fish oil carries the characteristic longer chain *n*-3 PUFAs, EPA, and DHA in greater proportion compared to *n*--6 PUFAs. The FA concentration of fish oil comprises 1%--4% LA; 10%--30% of α-linolenic acid, EPA, and DHA; 5%--30% of oleic acid; and 18%--35% of SFAs ([@B53]). However, the nature of FA concentration depends on fish species used, as indicated in [**Table 3**](#T3){ref-type="table"} ([@B53]; [@B35]). Three different formulations of FOLEs have been commercialized as detailed in [**Table 2**](#T2){ref-type="table"}.

Phytosterol content is not an issue associated with fish oil use in LEs as fish oil is not plant based ([@B12]). But the *n*-3 PUFAs been more prone to lipid peroxidation compared to *n*-6 PUFAs with more double bonds carried in their carbon chain ([@B80]). However the oxidative risk of FOLE is minimized by addition of α-tocopherol ([@B46]). In fact, FOLEs compared to other LEs characteristically carry the highest α-tocopherol content ranging from 150 to 296 mg/L ([**Table 2**](#T2){ref-type="table"}).

FOLE administration after abdominal surgery is reported to modulate increased EPA content of plasma FA concentration ([@B92]; [@B80]; [@B72]; [@B51]; [@B119]; [@B139]; [@B8]), platelets ([@B109]; [@B11]), and erythrocytes ([@B72]; [@B119]; [@B11]). Similarly, infusion of FOLE in sepsis patients reflected in increased *n*-3 FAs in plasma ([@B86]; [@B87]; [@B134]; [@B4]) and in mononuclear leukocyte membrane ([@B130]). This modulation of membrane lipids may favorably affect eicosanoids' profile and other lipid mediators generated from arachidonic acid and EPA.

### Comparative Studies of FOLE With SOLE, Physical Mixture MCT/LCT, and OOLE {#s4_5_1}

[**Table 4**](#T4){ref-type="table"} summarizes trials related to FOLE for PN administration compared to SOLE, physical mixture MCT/LCT LE and OOLE in abdominal surgery and critically ill patients. Abdominal surgery patients receiving fish oil in the PN regimen demonstrated decreased production of inflammatory eicosanoids ([@B92]; [@B130]; [@B67]; [@B51]; [@B139]; [@B135]) and cytokines ([@B130]; [@B138]; [@B77]; [@B145]; [@B28]). This may offset the surgery-induced decline in antigen presenting cell activity ([@B138]) and production of cytokines ([@B115]). Modulation of inflammatory mechanisms and inflammatory mediator production appears to be attenuated in septic and acute respiratory distress syndrome patients ([@B87]; [@B4]; [@B110]; [@B123]; [@B57]; [@B52]; [@B89]). Pro-inflammatory cytokines TNF-α, IL-β, IL-6, and IL-8 secretion were shown to be significantly reduced by endotoxin-stimulated mononuclear cells in the FOLE group whereas an increase occurred 2 days after SOLE infusion ([@B87]). Significant reduced levels of inflammatory mediators IL-6 and TNF-α were noted in critically ill patients on FOLE compared to SOLE (161) or MCT/LCT LE ([@B4]; [@B123]; [@B57]). Acute respiratory distress syndrome patients infused with FOLE in combination with MCT/LCT for 12 h had reduced leukotriene B4 production compared to SOLE alone ([@B110]). Reduced leukotriene B4 production was also observed in septic patients receiving FOLE in combination with OOLE (160). In contrast, fish oil provided at varied doses before and after surgery in malignant large bowel surgical patients did not show any immunosuppressive benefit ([@B115]). In patients undergoing abdominal aorta aneurysm repair ([@B8]) on MCT/LCT physical mixture or FOLE, no significant difference in the inflammatory marker CRP, in both groups of patients were noted.

Surgery patients administered with FOLE had higher plasma α-tocopherol concentration compared to SOLE, physical mixture MCT/LCT, or OOLE ([@B80]; [@B51]; [@B139]). Other metabolic outcomes reported were significant improvement in liver enzymes ([@B72]; [@B102]), reduced triglycerides ([@B142]; [@B84]), total bilirubin ([@B135]), low-density lipoprotein-cholesterol ([@B83]), and weight gain ([@B31]). However, only one study showed increased albumin levels in critically ill patients receiving FOLE infusion compared to OOLE ([@B52]).

Studies evaluating clinical benefit from FOLE administration compared to other LEs in surgical and critically ill patients report reduced mortality ([@B124]; [@B58]; [@B24]), shorter length of intensive care unit (ICU) ([@B58]) and hospital stay ([@B138]; [@B124]; [@B51]; [@B58]; [@B145]), lesser mechanical ventilation ([@B124]), reduced infections ([@B1]; [@B50]), improved oxygenation index and reduction in renal replacement therapy days ([@B134]), reduced antibiotic demand ([@B58]), and decreased incidence and duration of systemic inflammatory response syndrome ([@B66]; [@B145]). Significant patient clinical outcomes were observed when fish oil was provided before surgery ([@B124]). However there are studies reporting no superior benefits for their critically ill and surgical patients ([@B88]; [@B8]; [@B41]; [@B77]; [@B85]; [@B83]) when FOLE was prescribed with PN admixtures. Improvement in clinical outcomes is likely associated with dose of fish oil in PN ([@B124]; [@B58]). [@B58] observed reduced mortality with FOLE dosed at 0.1 g/kg/day, shorter length of ICU and hospital stays with FOLE doses between 0.1 and 0.2 g/kg/day, and antibiotic demand reduced by 23% with infusion doses of 0.15--0.2 g/kg/day ([@B58]).

#### Issues Associated With Use of FOLEs {#s4_5_1_1}

Since pure FOLE carries *n*-6 PUFA minimally, there is potential risk for essentially FA deficiency in patients administered with this emulsion as monotherapy. However some studies demonstrate patient success with single-therapy pure FOLE in pediatrics ([@B54]; [@B27]; [@B74]). It is suggested that essential FA deficiency prevention is possible with pure FOLE dosed at 1 g/kg/day ([@B54]; [@B74]).

Conclusions {#s5}
===========

This review relates fundamental knowledge on FA composition, functionality, and clinical evidence of lipids used in PN, which should be appreciated for future LE formulations. Clearly, LEs have evolved from just been a primary source of energy for PN to becoming therapeutic substrates capable of targeted outcomes in critically ill patients. It appears FA composition of LEs is the primary determinant of desired clinical outcomes, matched to its biological function. Options for LE choice becomes more specific based on performance outcomes as indicated for immuno-inflammatory, metabolic and clinical outcomes. Additionally the final composition of LE formulations must take into consideration the potential for essential FA deficiency, lipid peroxidation, phytosterol toxicity, hypertriglyceridemia, and hyperglycemia. It appears therefore, one type of LE alone cannot be uniformly applied to patients undergoing medical interventions.

We note that at this point, most clinical trials evaluating LEs describe only limited clinical outcomes. More studies reported the physical mixture MCT/LCT, STG-LE, and FOLE administrations benefit metabolic outcomes whereas studies on SOLE indicate greater risk on immuno-inflammatory outcomes. Current evidence is insufficient to support clinical benefits associated with FOLE use compared to OOLEs but some studies do report that fish oil included in PN may be beneficial for critically ill patients. More studies adequately powered, with standardized dosage and longer duration of supplementation are needed to indicate clear benefit of FOLE in hyperinflammatory states.
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